2019 CYIR Finalized
44 MUC5B promoter variant for RA without ILD compared to controls. Immunohistochemical staining of RA-ILD lung tissue demonstrates the localization of MUC5B protein in the metaplastic epithelia lining honeycomb cysts and the mucus in honeycomb cysts, similar to that observed in IPF. Comments 1. The MUC5B promoter variant is associated with RA-ILD and driven by the UIP-phenotype. 2. The point estimates for the association of the MUC5B promoter variant with RA-ILD are similar to those observed with IPF. 3. These findings suggest that the MUC5B promoter variant may be a genetic risk factor for the UIP pattern in general. 4. Genetic risk factors for ILD, in particular RA-ILD and IPF, may allow us to identify at-risk populations. OXYGEN THERAPY IN INTERSTITIAL LUNG DISEASE Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, Boccabella C, De Lauretis A, Stock CJW, Saunders P, Montgomery A, Hogben C, Stockford A, Pittet M, Brown J, Chua F, George PM, Molyneaux PL, Margaritopoulos GA, Kokosi M, Kouranos V, Russell AM, Birring SS, Chetta A, Maher TM, Cullinan P, Hopkinson NS, Banya W, Whitty JA, Adamali H, Spencer LG, Farquhar M, Sestini P, Wells AU, Renzoni EA. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open- label, mixed-method, crossover randomised controlled trial. The Lancet Respiratory medicine. 2018;6(10):759-70. Summary Oxygen desaturation is observed in many patients with interstitial lung disease (ILD) and contributes to the symp- toms experienced by these patients. There is little data for use of supplemental oxygen in ILD and extrapolations have been made using the chronic obstructive pulmonary dis- ease (COPD) literature. This extrapolation may be problem- atic given the more frequent and severe exercise—induced desaturation observed in ILD compared to COPD. Further, our 2011 treatment guidelines did not provide guidance on the use of supplemental oxygen therapy in patients with isolated exertional hypoxemia. This study aimed to assess the effects of ambulatory oxygen on health-related quality of life (HRQOL) in patients with ILD and exertional hypox- emia. They randomly assigned 84 patients to receive sup- plemental oxygen or no oxygen. They found that patients randomized to ambulatory oxygen therapy had significant improvements in HRQOL as measured by the King’s Brief Interstitial Lung Disease questionnaire (K-BILD) compared to no oxygen. While certain subdomains of the K-BILD (i.e. breathlessness and activity and chest symptoms) were significantly improved between those randomized to oxygen vs. no oxygen, the psychological subdomain did not reach statistical significance. This study suggests that supplemental oxygen therapy in ILD patients with isolated exertional hypoxemia is associated with improved HRQOL. Comments 1. This was the first randomized controlled trial assessing the effects of ambulatory oxygen on HRQOL in ILD. 2. Ambulatory oxygen is associated with improved HRQOL in patients with ILD and exertional hypoxemia. 3. This was a limited duration (2 weeks followed by cross-over for 2 weeks) study so the long-term effects of supplemental oxygen therapy on HRQOL in ILD remains unknown. 4. Despite the improvement in HRQOL with use of supplemental oxygen, there remain physical and psychosocial barriers to the use of ambulatory oxygen. TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS Newton CA, Zhang D, Oldham JM, Kozlitina J, Ma SF, Martinez FJ, Raghu G, Noth I, Garcia CK. Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2018. Summary In 2012, the results of the IPFNet sponsored PANTHER-IPF [Evaluating the Effectiveness of Prednisone, Azathioprine and N-acetylcysteine (NAC) in Patients with IPF] were published and demonstrated that patients randomized to the combination of prednisone, azathioprine and NAC had increased mortality, hospitalization and treatment-related severe side effects compared to placebo. The reason for this difference in harm was unknown. In this study, the authors hypothesized that leukocyte telomere length (LTL) would be associated with differential risk of harm observed in this trial, based on data from the lung transplant litera- ture. They measured LTL in the PANTHER-IPF cohort and two replication cohorts [one clinical trial (ACE-IPF, warfa- rin vs. placebo) and one observational cohort (University of Texas Southwestern)]. They found that the majority of patients in these cohorts had an LTL <10th percentile of normal. In PANTHER-IPF, exposure to prednisone, azathio- prine and NAC was associated with harm in those with an LTL <10th percentile (HR 2.84, 95% CI 1.02-7.87), but not in those with an LTL >= 10th percentile (p=0.49). This inter- action effect was also observed in the replication cohorts. This observation was not found in the NAC only arm or with warfarin. Comments 1. There was an interaction between LTL and immunosuppression on outcome (death, transplant, FVC decline or hospitalization) in patients with IPF in two clinical trial cohorts and an observa- tional cohort. ILD
Made with FlippingBook
RkJQdWJsaXNoZXIy MTM1ODMw